Resolve M Therapeutics has announced its exit from stealth as it builds a platform focused on pro-resolution biology for inflammatory and autoimmune diseases.

The company was created through a collaboration between Johnson & Johnson Innovation – JJDC Inc and General Inception. Resolve M is developing tools to identify and validate targets linked to immune resolution pathways, rather than suppressing immune activity broadly.

The platform is based on research from Nir Hacohen’s laboratory at the Broad Institute, which identified a myeloid cell state referred to as MS1. The company said MS1-related pathways could be used to modulate immune responses and restore tissue homeostasis after inflammation.

The launch is early-stage and no preclinical or clinical programme data have been disclosed. The announcement focuses on platform development and company formation rather than validated therapeutic candidates.

Nir Hacohen, professor of medicine at Harvard Medical School and a core member of the Broad Institute, said: “Our findings of a defined myeloid cell state with suppressive functions provides a platform for induction, or modulation, of immune cells and their functions for therapeutic purposes in diverse inflammatory conditions.”

Pro-resolution biology is an area of active investigation in immunology, with the aim of promoting natural resolution pathways after infection or injury. Previous approaches, including lipid mediator-based strategies, have shown limited clinical success, highlighting the translational challenges in this field.

Resolve M said it intends to use the MS1 cell state as a basis for target identification, validation and drug discovery. The company aims to study myeloid cell biology in vivo and in vitro to understand mechanisms that could be relevant to chronic inflammatory and autoimmune disorders.

Venkat Reddy, chief scientific officer of General Inception, said: “By targeting the body’s innate resolution mechanisms with translatable biomarkers, we can rapidly validate our approach in patients and make real-time adjustments. This integrated model, merging world-class science, purpose-built infrastructure, and deep operational expertise, allows us to shorten development timelines, accelerating our journey to deliver transformative treatments for patients with chronic inflammatory diseases.”

The company has not disclosed funding amounts, pipeline timelines, or therapeutic modalities. Resolve M said it will build an internal discovery platform to generate programmes in inflammatory diseases, but details of specific indications or assets have not been provided.

The exit from stealth reflects continued interest from venture and corporate investors in immunology platforms, particularly those focused on modulating immune responses rather than suppressing them. However, significant work remains to demonstrate whether MS1-based approaches can produce drug candidates with clear translational relevance and clinical benefit.

Independent validation, comparative benchmarking against existing immunomodulatory strategies, and demonstration of disease-modifying effects in vivo will be required to assess the platform’s potential. For now, Resolve M’s announcement represents a company formation and platform concept, rather than a therapeutic breakthrough.